Aquestive Therapeutics Files 8-K Disclosure
Ticker: AQST · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd, press-release
Related Tickers: AQST
TL;DR
AQST filed an 8-K on 3/30/26 with a press release, no major news yet.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on March 30, 2026, to disclose information under Regulation FD. The filing includes a press release and exhibits related to a meeting, with various graphic files attached. No specific financial figures or material events beyond the disclosure itself are detailed in the provided text.
Why It Matters
This filing indicates Aquestive Therapeutics is providing material information to the public, potentially impacting investor understanding of the company's current status or future plans.
Risk Assessment
Risk Level: low — The filing is a standard disclosure (Regulation FD) and does not appear to contain new material adverse information.
Key Numbers
- 0001398733-26-000022 — SEC Accession Number (Unique identifier for this specific filing)
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Filer of the 8-K
- 0001398733 (company) — CIK number for Aquestive Therapeutics, Inc.
- 2026-03-30 (date) — Filing date of the 8-K
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is Regulation FD Disclosure (Item 7.01) and to file Financial Statements and Exhibits (Item 9.01), including a press release.
When was this 8-K filing accepted by the SEC?
The filing was accepted on March 30, 2026, at 07:44:46.
What type of documents are included as exhibits with this filing?
The exhibits include a press release (EX-99.1) and several graphic files (typeameetingpressrelease001.jpg through 005.jpg).
What is the business address of Aquestive Therapeutics, Inc. mentioned in the filing?
The business address is 30 TECHNOLOGY DRIVE, WARREN NJ 07059.
Does the filing detail any specific financial results or material events?
The provided text does not detail specific financial results or material events beyond the fact that a press release and exhibits are being disclosed.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2026-03-30 07:44:46
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20260330.htm (8-K) — 27KB
- typeameetingpressrelease.htm (EX-99.1) — 18KB
- typeameetingpressrelease001.jpg (GRAPHIC) — 269KB
- typeameetingpressrelease002.jpg (GRAPHIC) — 333KB
- typeameetingpressrelease003.jpg (GRAPHIC) — 365KB
- typeameetingpressrelease004.jpg (GRAPHIC) — 337KB
- typeameetingpressrelease005.jpg (GRAPHIC) — 28KB
- 0001398733-26-000022.txt ( ) — 1999KB
- aqst-20260330.xsd (EX-101.SCH) — 2KB
- aqst-20260330_lab.xml (EX-101.LAB) — 21KB
- aqst-20260330_pre.xml (EX-101.PRE) — 12KB
- aqst-20260330_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 30, 2026, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing the receipt of preliminary comments and successful completion of an in-person Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the resubmission of the Company's New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film for the treatment of Type 1 allergic reactions, including anaphylaxis. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. Press Release, dated March 30, 2026 104 Cover Page Interaction Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 30, 2026 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer